Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Joins Qiagen Program to Accelerate Companion Diagnostic Commercialization

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that Laboratory Corporation of America has joined its "Day-One" lab readiness program designed to expedite patient access to Qiagen companion diagnostic products following regulatory approval of the tests and associated drugs.

Qiagen's Day-One program is intended to enable molecular diagnostic labs to begin preparing for commercial launch of new drugs and in vitro diagnostic tests being developed by Qiagen and its partners once US Food and Drug Administration approval is obtained.

This includes "pre-approval preparation of workflow implementation, training, assay verification, forecasting, medical communication, and reimbursement to ensure immediate test readiness," Thierry Bernard, senior vice president and head of Qiagen's molecular diagnostics business, said in a statement.

These tests include companion diagnostics based on next-generation sequencing and qPCR being prepared for launches in 2019 and 2020 in several countries. An example of such a test would be a Qiagen-developed companion diagnostic to guide the use of a Novartis investigational PI3K inhibitor in certain breast cancer patients.

Qiagen said that companion diagnostics for a wide range of cancers including lung, breast, colorectal, bladder, and eventually pan-tumor disease areas are currently in LabCorp's "Day One" lab readiness pipeline.

Qiagen has struck similar lab readiness deals with Japan's SRL and NeoGenomics.

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.